Is regorafenib a targeted drug? Which manufacturer produces it? Is it listed in China?

Regofenib is a targeted drug. It achieves the purpose of treating tumors by precisely acting on multiple tyrosine kinase targets in tumor cells to inhibit the proliferation, invasion and metastasis of tumor cells. This multi-target mechanism of action allows regorafenib to demonstrate good efficacy in the treatment of a variety of solid tumors. The drug is currently approved to treat colon or rectal cancer that has spread to other parts of the body (metastatic), gastrointestinal tumors that cannot be treated with surgery (GIST), and hepatocellular carcinoma (HCC). Regarding its manufacturer and its listing in the Chinese market, this article will provide detailed answers.

Regofenib is produced by Bayer AG of Germany, a world-renowned pharmaceutical company. Bayer relies on its strong R&D capabilities and rigorous production processes to ensure the quality and efficacy of regorafenib. Regorafenib has gained widespread recognition and application worldwide. With the booming market, Laos' ASEAN Pharmaceuticals and India's NATCO Pharmaceuticals have also launched generic versions of the drug at very affordable prices, providing patients with a variety of treatment options.

At present, regorafenib has been successfully launched in China. Since being approved by the National Medical Products Administration in 2017, regorafenib has been increasingly widely used in the Chinese market. It provides new treatment options for many cancer patients, especially those who have responded poorly to traditional treatments or have metastasized. Regorafenib has shown unique advantages. It is worth mentioning that regorafenib has been included in medical insurance, and patients can also enjoy reimbursement benefits. Please consult the local medical insurance bureau for specific reimbursement conditions and proportions.

To sum up, regorafenib, as a multi-target targeted drug, is produced by Bayer in Germany and successfully launched in China. It plays an important role in the field of anti-tumor treatment, bringing new hope and options to cancer patients. However, as a powerful drug, the use of regorafenib must be strictly followed by medical instructions to ensure patient safety and efficacy.